Transforming life for patients with Parkinson’s disease

Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.

Two clinical phase II candidates

Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more >

Pirepemat (IRL752) in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more >

Proprietary technology platform

The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more >

Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease.

Read more here >

Latest press release

IRLAB invites to a conference call in connection with the signed licensing deal with Ipsen for drug candidate mesdopetam

July 16, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) announced late yesterday that a licensing agreement has been entered with the global biopharmaceutical company Ipsen for the drug candidate mesdopetam. In connection with this, IRLAB invites investors, analysts and media to a conference call on July 16, 2021, at 10:00 CET.

Read More >
Latest presentation

CEO Nicholas Waters, CEO, participated at Redeye Growth Day 2021

June 2, 2021

Nicholas Waters, CEO, presented at Redeye Growth Day on June 2, 2021. The presentationen is followed by a Q&A and is held in English. Watch here >

Read More >

Subscribe